Dr. Sneha Swaroop,Lecturer
Information about Dr. Sneha Swaroop at the University of Bradford.
- School of Pharmacy & Medical Sciences
(Faculty of Life Sciences) - Email:
- s.swaroop@bradford.ac.uk
Biography
Dr Sneha Swaroop is an Assistant Professor in Cell and Molecular Biology at the School of Pharmacy and Medical Sciences. Her research focuses on stem cells in cancer, with the goal of identifying novel ways to target them and develop effective therapies for cancer patients. After earning her Masterâs degree in Biotechnology, Dr Swaroop pursued a Ph.D. in the field of Oncology from the renowned Cancer Institute (WIA), India, where she extensively researched the role of the hedgehog pathway in maintaining cancer stem cells in serous adenocarcinoma of the ovary. As a testament to her excellent research capabilities, Dr Swaroop was awarded the prestigious Schlumberger Faculty for the Future (FFTF) Fellowship, allowing her to undertake post- doctoral research in drug discovery at the Institute of Cancer Therapeutics (ICT), University of Bradford. In this role, she evaluated novel cancer stem cell-targeted chemical probes and drug candidates in breast and prostate cancer, which has the potential to transform cancer treatment. Aside from her research, Dr Swaroop is also a dedicated STEM ambassador and educator, mentoring and training the next generation of scientists. She is also committed to engaging with wider community, participating in public engagement activities increasing awareness and understanding of cancer research.
Research
Dr Sneha Swaroopâs research interests are centered around understanding the intricate biology of cancer stem cells and identifying novel ways to target them. Her research includes several noteworthy studies such as: 1) Characterising ovarian cancer stem cells (CSCs) using spheroid culture and evaluating the significance of embryonic signaling pathways.2) Identifying novel biomarkers for ovarian cancer stem cells using in silico approaches, establishing in vitro and in vivo models to study CSCs and evaluating novel therapeutic targets for improved treatment. 3) Evaluation of the effect of a dual PI3K δ/γ inhibitors on cancer stem cell proliferation in serous ovarian carcinoma. 4) Investigating stem cell gene expression in spheroids and deciphering splice variants of stem cell specific genes in teratoma and human embryonic stem cells followed by their analysis in two and three dimensional culture. 5) Establishing the role of CSCs in tumour angiogenesis and lymph angiogenesis in ovarian cancer.Moving forward, Dr Swaroop aims to continue exploring the biology of cancer stem cells in relation to the tumour microenvironment with the ultimate aim of developing more effective treatments for cancer patients. Currently Dr Swaroop is seeking motivated and passionate PhD students and Post Docs to explore the intricate self regulatory mechanisms of CSCs in ovarian cancer. Fellowship applications such as Schlumberger, Newton and Commonwealth from ideal candidates will be supported for conducting research in the filed of CSCs at the Institute of Cancer Therapeutics, Bradford. Please contact s.swaroop@bradford.ac.uk for more details.
Professional activities
Information about education, employment and areas of particular interest for Dr. Sneha Swaroop is as follows:
- UGC Research Fellowship in the year 01-JAN-10 (specified as 01/01/2010)
- UGC Senior Research Fellowship in the year 01-JAN-13 (specified as 01/01/2013)
- Schlumberger Faculty For the Future Fellowship in the year 01-MAR-19 (specified as 01/03/2019)
- Schlumberger Faculty For The Future- Renewal in the year 01-JAN-20 (specified as 01/01/2020)
- Schlumberger Faculty For the Future-Renewal in the year 01-JAN-21 (specified as 01/01/2021)
Publications
There are 17 publications involving or that are attributed to Dr. Sneha Swaroop. They are listed as:
- conference publication (1)
- peer reviewed journal (16)
Conference Publication
Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
---|---|---|---|---|---|---|---|---|---|---|---|
Abstract 1820: N,N-diethylaminobenzaldehyde-based small molecules to probe aldehyde dehydrogenase as target in prostate cancer | 2022 | Proceedings: AACR Annual Meeting | Proceedings: AACR Annual Meeting | Elisabet Batlle Rocafort; Ali I. Ibrahim; Maria Sadiq; Sneha Smarakan; Vibhu Jha; Tiziano Tuccinardi; Fiona Frame; Norman Maitland; Rafael Jiménez Aguilar; Raquel Pequerul Pavón; Xavier Parés Casampera; Goreti Ribeiro Morais; Jaume Farrés Vicen; Klaus Pors | Cancer Research | https://doi.org/10.1158/1538-7445.AM2022-1820 |
Peer Reviewed Journal
Title | Year | Publication name | Journal | Volume | Pages | Authors | Editors | ISSN | Publisher | DOI | Location |
---|---|---|---|---|---|---|---|---|---|---|---|
Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer | 2022 | Journal of Medicinal Chemistry | 65 | Ali I M Ibrahim, Elisabet Batlle, Smarakan Sneha, Rafael Jiménez, Raquel Pequerul, Xavier Parés, Till Rüngeler, Vibhu Jha, Tiziano Tuccinardi, Maria Sadiq, Fiona Frame, Norman J Maitland, Jaume Farrés, Klaus Pors | 10.1021/acs.jmedchem.1c01367 | ||||||
LASP-1 interacts with ErbB2 in ovarian cancer cells. | 2022 | Biochemical Journal | 479 | Sidhanth C;Bindhya S;Shabna A;Krishnapriya S;Manasa P;Nagare RP;Joshua T;Sneha S;Murhekar K;Ganesan TS; | 1470-8728 | 10.1042/BCJ20210173 | |||||
Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. | 2021 | Biomedicines | 9 | Sneha S;Baker SC;Green A;Storr S;Aiyappa R;Martin S;Pors K; | 2227-9059 | 10.3390/biomedicines9030290 | |||||
Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer. | 2021 | Scientific Reports | 11 | Presa D;Khurram SA;Zubir AZA;Smarakan S;Cooper PA;Morais GR;Sadiq M;Sutherland M;Loadman PM;McCaul J;Shnyder SD;Patterson LH;Pors K; | 2045-2322 | 10.1038/s41598-021-98217-z | |||||
ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo. | 2020 | Experimental Cell Research | 392 | Nagare RP;Sneha S;Krishnapriya S;Ramachandran B;Murhekar K;Vasudevan S;Shabna A;Ganesan TS; | 1090-2422 | 10.1016/j.yexcr.2020.112009 | |||||
Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours. | 2020 | Cancer Biomarkers : Section A Of Disease Markers | 28 | Nagare RP;Sneha S;Sidhanth C;Roopa S;Murhekar K;Shirley S;Swaminathan R;Sridevi V;Ganesan TS; | 1875-8592 | 10.3233/CBM-201463 | |||||
The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary. | 2020 | Cellular Oncology (Dordrecht) | 43 | Sneha S;Nagare RP;Sidhanth C;Krishnapriya S;Garg M;Ramachandran B;Murhekar K;Sundersingh S;Ganesan TS; | 2211-3436 | 10.1007/s13402-020-00504-w | |||||
Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. | 2019 | Angiogenesis | 22 | Krishnapriya S;Sidhanth C;Manasa P;Sneha S;Bindhya S;Nagare RP;Ramachandran B;Vishwanathan P;Murhekar K;Shirley S;Ganesan TS; | 1573-7209 | 10.1007/s10456-019-09669-x | |||||
Analysis of Human Stem Cell Transcription Factors. | 2019 | Cellular Reprogramming | 21 | Sneha S;Nagare RP;Manasa P;Vasudevan S;Shabna A;Ganesan TS; | 2152-4998 | 10.1089/cell.2019.0005 | |||||
Analysis of hematopoietic stem cells using a composite approach. | 2019 | International Journal of Biochemistry and Cell Biology | 109 | Nagare RP;Sneha S;Ramesh S;Ganesan TS; | 1878-5875 | 10.1016/j.biocel.2019.02.003 | |||||
A systematic understanding of signaling by ErbB2 in cancer using phosphoproteomics. | 2018 | Biochemistry and cell biology = Biochimie et biologie cellulaire | 96 | Sidhanth C;Manasa P;Krishnapriya S;Sneha S;Bindhya S;Nagare RP;Garg M;Ganesan TS; | 1208-6002 | 10.1139/bcb-2017-0020 | |||||
Therapeutic antibodies against cancer stem cells: a promising approach. | 2017 | Cancer Immunology, Immunotherapy | 66 | Sneha S;Nagare RP;Priya SK;Sidhanth C;Pors K;Ganesan TS; | 1432-0851 | 10.1007/s00262-017-2049-0 | |||||
Cancer Stem Cells - Are Surface Markers Alone Sufficient? | 2017 | Current Stem Cell Research and Therapy | 12 | Nagare RP;Sneha S;Priya SK;Ganesan TS; | 2212-3946 | 10.2174/1574888x11666160607211436 | |||||
Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. | 2017 | Scientific Reports | 7 | Garg M;Kanojia D;Mayakonda A;Ganesan TS;Sadhanandhan B;Suresh S;S S;Nagare RP;Said JW;Doan NB;Ding LW;Baloglu E;Shacham S;Kauffman M;Koeffler HP; | 2045-2322 | 10.1038/s41598-017-10325-x | |||||
Tumour angiogenesis-Origin of blood vessels. | 2016 | International Journal of Cancer | 139 | Krishna Priya S;Nagare RP;Sneha VS;Sidhanth C;Bindhya S;Manasa P;Ganesan TS; | 1097-0215 | 10.1002/ijc.30067 | |||||
Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity. | Indian Heart Journal | 70 | Vinodhini MT;Sneha S;Nagare RP;Bindhya S;Shetty V;Manikandan D;Ganesan P;Sagar TG;Ganesan TS; | 2213-3763 | 10.1016/j.ihj.2017.07.001 |